论文部分内容阅读
目的 评价乳腺癌肝转移介入治疗疗效 ,探讨其在乳腺癌肝转移综合治疗中的价值。方法 1 993～ 1 998年对 3 4例肝转移乳腺癌患者共进行 73次介入治疗 ,药物选择为表阿霉素(EADM) ,顺铂 (DDP) ,丝裂霉素 (MMC) ,5 氟尿嘧啶 (5 FU)等。其中 2 2例行超液化碘油栓塞。结果应用世界卫生组织 (WHO)实体瘤测量标准评价治疗后疗效 ,3 4例中完全缓解 (CR) 6例 (1 7 65% ) ,部分缓解 (PR) 1 2例 (3 5 2 9% ) ,无变化 (NC) 1 0例 (2 9 41 % ) ,进展 (PD) 6例 (1 7 65% )。总有效率为52 94%。 1、2、3、4年累积生存率分别为 :56 90 %、2 5 0 0 %、5 0 0 %、5 0 0 %。累积中位生存期为1 1 5个月。结论 乳腺癌肝转移的介入治疗疗效显著 ,毒副作用小 ,应作为乳腺癌肝转移综合治疗中的主要治疗手段。
Objective To evaluate the efficacy of interventional treatment for breast cancer liver metastases and explore its value in the comprehensive treatment of breast cancer liver metastases. Methods From 1993 to 1 998, 73 interventional treatments were performed on 34 patients with liver metastases. The drug options were epirubicin (EADM), cisplatin (DDP), mitomycin (MMC), and 5-fluorouracil. (5 FU) and so on. Among them, 2 were routinely performed lipiodol embolization. Results The therapeutic effect was evaluated by using WHO solid tumor measurement criteria. Complete remission (CR) was found in 6 patients (176.5%) and partial remission (PR) was observed in 32 patients (3 5 2 9%). There were no changes (NC) in 10 cases (29.41%) and progression (PD) in 6 cases (17.65%). The total effective rate is 52 94%. The cumulative survival rates at 1, 2, 3, and 4 years were: 56 90%, 2 50%, 50%, and 50%. The cumulative median survival was 1 15 months. Conclusion The interventional treatment of liver metastases from breast cancer has significant curative effect and small side effects. It should be used as the main treatment in the comprehensive treatment of liver metastases of breast cancer.